Lung Cancer Clinical Trials
An Open-label, Randomized Phase 3 trial comparing the study drug ASP8273 to erlotinib or gefitinib in previously
untreated patients diagnosed with Stage IIIB/IV non-small cell lung cancer tumors that have EGFR-
activating mutations. This study is open to patients who are newly diagnosed or have recurrent disease;
who have locally advanced, metastatic non-small cell lung cancer that cannot be surgically removed; and
who have not received treatment targeting EGFR mutations. If patients have received treatment before,
or during chemotherapy (“neoadjuvant” or “adjuvant”), this must be completed 6 months before
starting the study.
Phase 2 trial of the study drug, tesevatinib, in patients with non-small cell lung cancer who
have an EGFR-activating mutation, have had prior treatment with a “tyrosine kinase inhibitor” (TKI), and
who have had their disease spread to the brain (brain metastases), or to the membranes surrounding
the brain and spinal cord (leptomeningeal metastases). Patients must not take medication known to
moderately or severely inhibit the CYP3A4 isozyme, or take any drugs that are CYP3A4 inducers. Patients
must not take any drugs associated with abnormal heart arrhythmia.
Development of a Method for Extraction and Analysis of Cell-Free Nucleic Acids from Urine – Open to all patients except those with any of the following conditions:
- Hepatitis B
- Hepatitis C
- Low Blood Pressure
ELUXA 6: Phase II single-arm, open-label study of BI 1482694 in patients with locally advanced or metastatic NSCLC harboring a T790M mutation as detected in cell-free DNA in plasma following progression on or after at least one prior EGFR TKI treatment.
For more information about Beverly Hills Cancer Center's comprehensive clinical research programs and trials currently available to patients, please contact us at (310) 432-8932 or click here to send in an inquiry.
Schedule a Consultation Today!
Your health is important, and we welcome the opportunity to help you heal.
To schedule an appointment, please call Beverly Hills Cancer Center in Beverly Hills, California at (877) 320-5131 or use our interactive Online Appointment Request Form.